<DOC>
	<DOCNO>NCT01400035</DOCNO>
	<brief_summary>Trial Title：The treatment Vinpocetine（Cavinton）in patient cerebral infarction , open , randomize , multi-center control study 1 . Objectives Evaluate efficacy safety Vinpocetine（Cavinton）for treatment cerebral infarction 2 . Design Open , randomize , multi-center control study 3 . Trial Population : Patients acute cerebral infarction 4 . Number Subjects 720 patient test group 240 patient control group , totally 960 patient recruit . 5 . Administration Test group : intravenous infusion drip Vinpocetine 30 mg Citicoline 0.4g daily ; additionally oral take aspirin 75-100mg clopidogrel sulfate tablet 75mg day . Control group : intravenous infusion drip Citicoline 0.4g daily ; additionally oral take aspirin 75-100mg clopidogrel sulfate tablet 75mg day . 6 . Outcome evaluation 6.1 Primary end point : 6.1.1 Modified Rankin Scale . 6.1.2 Mini-Mental State Examination ( MMSE ) 6.2 Second end point 6.2.1 Barthel index 6.2.2 NIHSS score 6.2.3 Transcranial Doppler ( TCD ) examination 6.3 Safety data 6.3.1 Serology , hepatic renal function examination 6.3.2 Adverse event 7 . Statistical Analysis : SPSS 11.0 use make data analysis .</brief_summary>
	<brief_title>Chinese Assessment Vinpocetine In Neurology</brief_title>
	<detailed_description>The design study randomize , open , multi-center control study . The patient cerebral infarction study object . Coronal CT / MRI examination combine NIHSS Modified Ranking Scale , MMSE , Barthel index , Transcranial Doppler ( TCD ) examination apply evaluate Vinpocetine treatment efficacy safety cerebral infarction [ 14 ] . From ethical side , patient receive conventional therapy , base , test group give intravenous injection Vinpocetine add-on treatment . Observation period 10-14 day , follow 3 month .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Vinpocetine</mesh_term>
	<mesh_term>Cytidine Diphosphate Choline</mesh_term>
	<criteria>Male female , age 4080 The onset infarction 48 hour 1 month CT / MRI result show cerebral infarction deficit neurological function . CT MRI confirm intracranial hemorrhage NIHSS score ≥ 3 The subject agree sign inform consent form Evidence acute chronic intracranial hemorrhage , subarachnoid hemorrhage , intracranial arteriovenous malformation , aneurysm neoplasm base CT / MRI examination NIHSS score ≥ 17 Coma patient Existed disorder condition would interfere neurological assessment ( eg . dementia , psychiatric disorder , etc . ) Intracranial tumor , arteriovenous malformation , aneurysm , intracranial surgery Active peptic ulcer disease Complicated severe hepatic renal disorder ( ALT , AST 3.0 time higher normal value ; BUN Cr 1.5 time normal value ) severe disorder hematopoietic system endocrine system . Bleeding tendency blood disease Plan perform operation carotid angioplasty With severe congestive heart failure acute myocardial infarction Participate clinical trial time , withdrawal within 3 month Allergic contraindicate vinpocetine treatment medication Investigator think subject suitable participate trial</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>acute cerebral infarction , Vinpocetine</keyword>
</DOC>